CN118973584A - Kras g12c抑制剂和tead抑制剂的治疗组合 - Google Patents

Kras g12c抑制剂和tead抑制剂的治疗组合 Download PDF

Info

Publication number
CN118973584A
CN118973584A CN202380032305.8A CN202380032305A CN118973584A CN 118973584 A CN118973584 A CN 118973584A CN 202380032305 A CN202380032305 A CN 202380032305A CN 118973584 A CN118973584 A CN 118973584A
Authority
CN
China
Prior art keywords
group
substituted
atoms
alkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032305.8A
Other languages
English (en)
Chinese (zh)
Inventor
J-C·勒贝尔
J·莫尔
S·塔玛卡罗
I·瓦尔廷戈耶尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN118973584A publication Critical patent/CN118973584A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380032305.8A 2022-04-04 2023-04-03 Kras g12c抑制剂和tead抑制剂的治疗组合 Pending CN118973584A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305439 2022-04-04
EP22305439.6 2022-04-04
PCT/EP2023/058693 WO2023194310A1 (en) 2022-04-04 2023-04-03 Therapeutic combination of kras g12c inhibitor and tead inhibitor

Publications (1)

Publication Number Publication Date
CN118973584A true CN118973584A (zh) 2024-11-15

Family

ID=81326107

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032305.8A Pending CN118973584A (zh) 2022-04-04 2023-04-03 Kras g12c抑制剂和tead抑制剂的治疗组合

Country Status (5)

Country Link
US (1) US20250295664A1 (https=)
EP (1) EP4504203A1 (https=)
JP (1) JP2025511161A (https=)
CN (1) CN118973584A (https=)
WO (1) WO2023194310A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7039489B2 (ja) 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
HRP20230377T1 (hr) 2017-11-15 2023-06-23 Mirati Therapeutics, Inc. Inhibitori mutacije kras g12c
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020055761A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
TW202128699A (zh) * 2019-11-27 2021-08-01 美商建南德克公司 治療性化合物
US20230140808A1 (en) 2020-04-07 2023-05-04 Sanofi (1 H-Indol-5-YL)Acrylamide Derivatives as Inhibitors of Tead Proteins and the Hippo-YAP1/TAZ Signaling Cascade for the Treatment of Cancer
US11787775B2 (en) * 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
JP7774612B2 (ja) 2020-07-30 2025-11-21 サノフイ アクリルアミド置換インダン化合物およびその治療的使用

Also Published As

Publication number Publication date
EP4504203A1 (en) 2025-02-12
JP2025511161A (ja) 2025-04-15
WO2023194310A1 (en) 2023-10-12
US20250295664A1 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
EP2475659B1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
EP2598508B1 (en) Isoxazolo-quinazolines as modulators of protein kinase activity
CN103957709A (zh) Mek抑制剂与奥诺拉(aurora)a激酶选择性抑制剂的组合
CN117447479B (zh) 一种靶向肿瘤免疫激酶的吡咯并吡嗪衍生物、制备方法及其应用
JP2022500384A (ja) 組み合わせ療法
JP2022500388A (ja) 組み合わせ療法
CA3163095A1 (en) Combination therapy involving diaryl macrocyclic compounds
US20110059961A1 (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
CN118973584A (zh) Kras g12c抑制剂和tead抑制剂的治疗组合
US12508245B2 (en) Co-therapies including a metastasis inhibitor
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
AU2015266552A1 (en) Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
EP4441052B1 (en) Compounds
CN117447470B (zh) 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用
HK40118235A (zh) 用於治疗或预防癌症的喹啉衍生物
Ma ALKYNYL AMINOISOQUINOLINES, NOVEL FLT3 KINASE INHIBITORS WITH POTENT ACTIVITY AGAINST ACUTE MYELOID LEUKEMIA

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination